Andrew Phillips
Senior Director Abbvie
Seminars
Thursday 5th November 2026
Panel Discussion: Maximize the Value of Classical Payloads Through Smarter Design & Better Development Decisions
3:30 pm
- Assess whether the performance ceiling of established payloads is driven by the payload itself or by broader ADC design factors, including antibody biology, internalization dynamics, and target selection
- Explore the impact of tumor biology and cell-cycle kinetics on ADC efficacy, discussing whether reliance on traditional cytotoxic mechanisms leaves significant tumor populations untreated and how developers can address these limitations
- Examine how linker design, payload permeability, and medicinal chemistry have been used to fine-tune bystander killing, highlighting lessons from both efficacy gains and toxicity liabilities
- Debate how antibody engineering, immune-mediated mechanisms of action, and novel ADC platforms can unlock greater value from proven payload classes without requiring entirely new warheads
Wednesday 4th November 2026
Expanding the ADC Therapeutic Window to Improve Safety, Efficacy, & Clinical Success
1:00 pm
This workshop examines one of the central tensions in ADC development, asking how potent is too potent. It explores whether increasing payload potency truly expands the therapeutic window or simply shifts toxicity into new and sometimes less predictable profiles. Through case based discussion, the session will analyze how DAR optimization, site specific conjugation, linker selection and payload characteristics collectively shape safety, efficacy and clinical usability
- Examine how payload permeability, linker stability and intracellular release location collectively determine safety margins and clinical feasibility
- Challenge the assumption that extreme payload potency is always required for ADC success, tracing where this paradigm originated and when it no longer holds
- Discuss trade‑offs between payload potency, off‑target toxicity, dosing flexibility, and clinical tolerability
- Explore practical strategies to balance potency, dosing flexibility and tolerability including mechanism selective payload design and refined conjugation approaches to improve therapeutic index
